Lymphoma and Luekemia in Rheumatoid Arthritis

Williams, Colin P.; Blöch, D.; Sibley, John; Haga, May; Wolfe, Fred; Raynauld, Jean‐Pierre; Singh, Gurkirpal; Hickey, Anne R.; Fries, James F.

doi:10.1097/00124743-199604000-00002

Cited by 20 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We cannot exclude in our patient a diagnosis of a rare methotrexate‐induced lymphoma. However, most reported cases of methotrexate‐related lymphoma in RA have been large or polymorphous B‐cell non‐Hodgkin's lymphoma 15,16 . While methotrexate increases the risk of lymphoma in RA patients slightly (odds ratio 1.7), RA itself is considered to be a risk factor for developing lymphoproliferative disease 16 .…”

Section: Discussionmentioning

confidence: 99%

“…However, most reported cases of methotrexate‐related lymphoma in RA have been large or polymorphous B‐cell non‐Hodgkin's lymphoma 15,16 . While methotrexate increases the risk of lymphoma in RA patients slightly (odds ratio 1.7), RA itself is considered to be a risk factor for developing lymphoproliferative disease 16 . In a recent review of the 50 cases described so far, spontaneous remission has been noted in eight cases after methotrexate was ceased 15 .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Stage IV CD30+ anaplastic large cell lymphoma: Response to acitretin and interferon‐α

et al. 2002

View full text Add to dashboard Cite

Retinoids and interferon (IFN)-alpha induce differentiation, affect cell proliferation and alter various immune parameters. In combination, their effects may be additive or even synergistic in the treatment of malignancy. We present a 53-year-old woman with stage IV CD30+ anaplastic large cell lymphoma with brain, lung and skin involvement. The patient had been on methotrexate for rheumatoid arthritis. After a combination of oral acitretin 50 mg daily and IFN-alpha 3 million units subcutaneously 3 times per week, the skin lesions cleared within 2 months, lung lesions by 5 months and brain lesions by 7 months. Although we cannot exclude that methotrexate played a role in the development of this lymphoma and that its withdrawal contributed to the clearance of lesions, we propose that the patient's disease responded to the combination of acitretin and IFN-alpha.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Stage IV CD30+ anaplastic large cell lymphoma: Response to acitretin and interferon‐α

et al. 2002

View full text Add to dashboard Cite

show abstract

“…It is suggested that the causal relationship between renal malignancy and rheumatoid disease is related to age and disease course, and the earlier the onset of rheumatoid disease may be a protective factor for renal malignancy. In addition, due to the use of a large number of immunosuppressive drugs in the treatment of patients with systemic autoimmune, some scholars believe that the occurrence of malignant tumors is related to drug use to a certain extent, and azathioprine may increase the risk of lymphoma and other malignant tumors in patients with RA [48][49][50]. Since this drug is usually used only for patients with severe disease, these findings are likely to be confused with the severe features of the disease itself.…”

Section: Plos Onementioning

confidence: 99%

Causal relationship between several autoimmune diseases and renal malignancies: A two-sample mendelian randomization study

Liu,

Luo,

Zhao

et al. 2024

PLoS ONE

View full text Add to dashboard Cite

Objective Observational studies have shown an association between systemic autoimmune disease (AD) and multiple malignancies. However, due to the difficulty indetermining the temporal nature of the order, their causal relationship remains elusive. Based on pooled data from a large population-wide genome-wide association study (GWAS), this study explores the genetic causality between systemic autoimmune disease and renal malignancy. Methods We took a series of quality control steps from a large-scale genome-wide association study to select single nucleotide polymorphisms (SNPs) associated with systemic autoimmune disease as instrumental variables(IVs) to analyze genetic causality with renal malignancies. Inverse variance weighting (IVW), MR- Egger, weighted median, simple model and weighted model were used for analysis. The results were mainly based on IVW (Random Effects), followed by sensitivity analysis. Inverse-Variance Weighted(IVW) and MR-Egger were used to test for heterogeneity. MR- Egger is also used for pleiotropic testing. A single SNP analysis was used to identify single nucleotide polymorphisms (SNPs) with potential impact. Odds ratio (OR) and 95% confidence interval (CI) were used to evaluate causality, and sensitivity analysis was performed to evaluate pleiotropy and instrumental validity. Results Acute and subacute iridocylitis (P = 0.006, OR = 1.077), Ankylosing spondylitis (P = 0.002, OR = 1.051), and spondyloarthritis (P = 0.009, OR = 1.073) were positively associated with an increased risk of renal malignancy. Coxarthrosis (P = 0.008, OR = 0.483), Juvenile rheumatism (P = 0.011, OR = 0.897), and Systemic lupus erythematosus (P = 0.014, OR = 0.869) were negatively associated with an increased risk of renal malignancy. The results of sensitivity analysis were consistent without heterogeneity or pleiotropy. Conclusion Our study suggests a causal relationship between different systemic autoimmune diseases and renal malignancies. These findings prompt health care providers to take seriously the potential risk of systemic autoimmune disease and provide new insights into the genetics of kidney malignancies.

show abstract